DK3207941T3 - Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater - Google Patents
Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater Download PDFInfo
- Publication number
- DK3207941T3 DK3207941T3 DK17151480.5T DK17151480T DK3207941T3 DK 3207941 T3 DK3207941 T3 DK 3207941T3 DK 17151480 T DK17151480 T DK 17151480T DK 3207941 T3 DK3207941 T3 DK 3207941T3
- Authority
- DK
- Denmark
- Prior art keywords
- diphtheritoxin
- conjugates
- interleukin
- methods
- compositions based
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84347106P | 2006-09-07 | 2006-09-07 | |
US93277207P | 2007-06-01 | 2007-06-01 | |
EP07837840.3A EP2063907B1 (en) | 2006-09-07 | 2007-09-07 | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3207941T3 true DK3207941T3 (da) | 2020-03-30 |
DK3207941T6 DK3207941T6 (da) | 2020-11-09 |
Family
ID=39157851
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07837840.3T DK2063907T3 (da) | 2006-09-07 | 2007-09-07 | Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater |
DK17151480.5T DK3207941T6 (da) | 2006-09-07 | 2007-09-07 | Fremgangsmåder og sammensætninger baseret på diphtheritoksin-interleukin-3-konjugater |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07837840.3T DK2063907T3 (da) | 2006-09-07 | 2007-09-07 | Fremgangsmåder og sammensætninger baseret på difteritoksin-interleukin-3-konjugater |
Country Status (17)
Country | Link |
---|---|
US (7) | US7763242B2 (da) |
EP (3) | EP3520806B1 (da) |
JP (7) | JP5550905B2 (da) |
AU (1) | AU2007293047B2 (da) |
CA (5) | CA3053981C (da) |
CY (2) | CY1119654T1 (da) |
DK (2) | DK2063907T3 (da) |
ES (2) | ES2646545T3 (da) |
FR (1) | FR21C1017I2 (da) |
HU (2) | HUE048356T2 (da) |
LT (2) | LT3207941T (da) |
LU (1) | LUC00206I2 (da) |
NL (1) | NL301103I2 (da) |
PL (2) | PL2063907T3 (da) |
PT (1) | PT3207941T (da) |
SI (1) | SI3207941T1 (da) |
WO (1) | WO2008030539A2 (da) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1692113T3 (da) | 2003-11-14 | 2018-01-08 | Lorus Therapeutics Inc | Arylimidazoler og anvendelse heraf som anticancermidler |
SI3207941T1 (sl) | 2006-09-07 | 2020-08-31 | Scott & White Memorial Hospital | Postopki in sestavki na osnovi konjugatov toksina davice-interlevkin-3 |
US8129341B2 (en) | 2008-08-25 | 2012-03-06 | New York University | Methods for treating diabetic wounds |
EP2352526A1 (en) * | 2008-09-19 | 2011-08-10 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
NZ601760A (en) * | 2010-02-17 | 2013-10-25 | Csl Ltd | Compositions and methods for targeting type 1 interferon producing cells |
EP3272352B1 (en) | 2010-06-17 | 2022-04-13 | New York University | Therapeutic and cosmetic uses and applications of calreticulin |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
US20130224191A1 (en) | 2010-08-27 | 2013-08-29 | Robert A. Stull | Notum protein modulators and methods of use |
BR112013005116A2 (pt) | 2010-09-03 | 2019-09-24 | Stem Centrx Inc | moduladores e métodos de uso |
PE20171143A1 (es) | 2010-12-08 | 2017-08-10 | Stem Centrx Inc | Nuevos moduladores y metodos para su uso |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
PE20190658A1 (es) | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
EP3539985A1 (en) | 2012-02-24 | 2019-09-18 | AbbVie Stemcentrx LLC | Anti sez6 antibodies and methods of use |
HUE043851T2 (hu) | 2013-02-22 | 2019-09-30 | Abbvie Stemcentrx Llc | Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk |
SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
EP3038634A4 (en) | 2013-08-28 | 2017-10-11 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
KR20160058960A (ko) * | 2013-10-04 | 2016-05-25 | 압토스 바이오사이언시스 인코포레이티드 | 암을 치료하기 위한 조성물과 방법 |
US10053511B2 (en) | 2013-11-06 | 2018-08-21 | Abbvie Stemcentrx Llc | Anti-claudin antibodies and methods of use |
AU2014361856A1 (en) | 2013-12-12 | 2016-06-30 | Abbvie Stemcentrx Llc | Novel anti-DPEP3 antibodies and methods of use |
JP2017514143A (ja) | 2014-02-21 | 2017-06-01 | アッヴィ・ステムセントルクス・エル・エル・シー | メラノーマに使用するための抗dll3抗体および薬物コンジュゲート |
BR112016025291A2 (pt) | 2014-04-30 | 2017-12-26 | Abbvie Stemcentrx Llc | conjugados de anticorpo anti-ptk7-fármaco |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
CA3021098A1 (en) | 2016-04-21 | 2017-10-26 | Abbvie Stemcentrx Llc | Novel anti-bmpr1b antibodies and methods of use |
CN107793481A (zh) * | 2016-08-31 | 2018-03-13 | 南京传奇生物科技有限公司 | 一种靶向人cd123的嵌合受体配体及其应用 |
US11149047B2 (en) | 2017-10-30 | 2021-10-19 | Aptose Biosciences, Inc. | Aryl imidazoles for treatment of cancer |
US20210361744A1 (en) * | 2018-04-27 | 2021-11-25 | Stemline Therapeutics, Inc. | Methods of Treating an Autoimmune Disease with a Human Interleukin-3 (IL-3)-Diphtheria Toxin Conjugate (DT-IL3) |
EP3802834A4 (en) * | 2018-05-30 | 2022-08-03 | The Governing Council of the University of Toronto | METHODS AND KITS FOR IDENTIFYING A PROTEIN ASSOCIATED WITH RECEPTOR-LIGAND INTERACTIONS |
BR112021007945A2 (pt) | 2018-10-31 | 2021-08-03 | Stemline Therapeutics, Inc. | método de terapia de combinação para tratar neoplasmas mieloproliferativos com um conjugado de toxina de difteria-interleucina-3 humana em combinação com outros agentes |
WO2020112642A1 (en) | 2018-11-30 | 2020-06-04 | Stemline Therapeutics, Inc. | Improved methods of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate |
EP4061967A1 (en) * | 2019-11-21 | 2022-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml) |
EP4259103A1 (en) | 2020-12-10 | 2023-10-18 | Stemline Therapeutics Inc. | Improved lyophilized formulation |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3369466D1 (en) | 1982-05-12 | 1987-03-05 | Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
US5080898A (en) | 1982-05-12 | 1992-01-14 | The University Hospital | Enzymatically active toxin coupled to a cell-specific ligand |
US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
DK0517829T4 (da) | 1990-03-02 | 2008-03-03 | Boston Medical Ct Corp | Forbedrede kimæriske toksiner |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
DE4121547A1 (de) | 1991-06-28 | 1993-01-14 | Daimler Benz Ag | Mehrschichtisolierfolie |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
DE4140121C2 (de) | 1991-12-05 | 1994-06-30 | Manfred Mueller | Verfahren zum Herstellen von gefaßten, gegossenen Schmuckstücken |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
AU5965296A (en) * | 1995-05-31 | 1996-12-18 | Regents Of The University Of Minnesota | Recombinant polypeptide cytotoxins for cancer treatment |
US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
US20040013664A1 (en) | 1997-01-14 | 2004-01-22 | Gentz Reiner L. | Tumor necrosis factor receptors 6 alpha & 6 beta |
US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
CA2393132A1 (en) | 1999-12-03 | 2001-06-07 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Dendritic cell-specific antibodies |
AU5003001A (en) | 2000-03-06 | 2001-09-17 | Univ Kentucky Res Found | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
EP1372720A4 (en) | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
AU2002322478A1 (en) | 2001-03-02 | 2002-12-16 | Medimmune, Inc. | Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders |
AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
SI3207941T1 (sl) | 2006-09-07 | 2020-08-31 | Scott & White Memorial Hospital | Postopki in sestavki na osnovi konjugatov toksina davice-interlevkin-3 |
AU2014201901B2 (en) | 2006-09-07 | 2016-05-05 | Scott & White Healthcare | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
WO2013130917A1 (en) | 2012-02-29 | 2013-09-06 | Ambrx, Inc. | Interleukin-3 polypeptide conjugates their uses |
-
2007
- 2007-09-07 SI SI200732148T patent/SI3207941T1/sl unknown
- 2007-09-07 EP EP19159793.9A patent/EP3520806B1/en active Active
- 2007-09-07 WO PCT/US2007/019481 patent/WO2008030539A2/en active Application Filing
- 2007-09-07 EP EP07837840.3A patent/EP2063907B1/en active Active
- 2007-09-07 CA CA3053981A patent/CA3053981C/en active Active
- 2007-09-07 DK DK07837840.3T patent/DK2063907T3/da active
- 2007-09-07 ES ES07837840.3T patent/ES2646545T3/es active Active
- 2007-09-07 AU AU2007293047A patent/AU2007293047B2/en active Active
- 2007-09-07 ES ES17151480T patent/ES2781402T7/es active Active
- 2007-09-07 EP EP17151480.5A patent/EP3207941B3/en active Active
- 2007-09-07 JP JP2009527415A patent/JP5550905B2/ja active Active
- 2007-09-07 CA CA2698595A patent/CA2698595C/en active Active
- 2007-09-07 US US11/899,747 patent/US7763242B2/en active Active
- 2007-09-07 PT PT171514805T patent/PT3207941T/pt unknown
- 2007-09-07 CA CA3007075A patent/CA3007075C/en active Active
- 2007-09-07 PL PL07837840T patent/PL2063907T3/pl unknown
- 2007-09-07 DK DK17151480.5T patent/DK3207941T6/da active
- 2007-09-07 LT LTEP17151480.5T patent/LT3207941T/lt unknown
- 2007-09-07 HU HUE17151480A patent/HUE048356T2/hu unknown
- 2007-09-07 CA CA2923381A patent/CA2923381A1/en not_active Abandoned
- 2007-09-07 CA CA3153438A patent/CA3153438C/en active Active
- 2007-09-07 PL PL17151480T patent/PL3207941T6/pl unknown
-
2009
- 2009-02-09 US US12/368,048 patent/US8470307B2/en active Active
-
2013
- 2013-05-17 US US13/896,923 patent/US9181317B2/en active Active
-
2014
- 2014-04-01 JP JP2014075847A patent/JP5902223B2/ja active Active
-
2015
- 2015-07-17 US US14/802,398 patent/US9631006B2/en active Active
-
2016
- 2016-03-09 JP JP2016045210A patent/JP6336500B2/ja active Active
-
2017
- 2017-03-10 US US15/455,420 patent/US10259853B2/en active Active
- 2017-11-03 CY CY20171101153T patent/CY1119654T1/el unknown
-
2018
- 2018-05-02 JP JP2018088719A patent/JP6654660B2/ja active Active
-
2019
- 2019-02-08 US US16/271,456 patent/US11130792B2/en active Active
-
2020
- 2020-01-30 JP JP2020013230A patent/JP2020079260A/ja active Pending
- 2020-03-23 CY CY20201100271T patent/CY1123035T1/el unknown
-
2021
- 2021-04-22 HU HUS2100013C patent/HUS2100013I1/hu unknown
- 2021-05-11 FR FR21C1017C patent/FR21C1017I2/fr active Active
- 2021-05-12 NL NL301103C patent/NL301103I2/nl unknown
- 2021-05-12 LU LU00206C patent/LUC00206I2/en unknown
- 2021-05-12 LT LTPA2021507C patent/LTC3207941I2/lt unknown
- 2021-08-25 US US17/411,947 patent/US20220235108A1/en active Pending
-
2022
- 2022-02-15 JP JP2022020917A patent/JP2022065089A/ja active Pending
-
2024
- 2024-04-04 JP JP2024060550A patent/JP2024088720A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3207941T3 (da) | Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater | |
DK3263589T5 (da) | Peptidsekvenser og sammensætninger | |
DK2570467T3 (da) | Sammensætninger af tetrafluorpropen og carbonhydrider | |
DK2444807T3 (da) | Mono- og dinitropyrazolhaptenkonjugater | |
DK1912671T3 (da) | Beta-glucuronid-linker-lægemiddelkonjugater | |
DK2087002T3 (da) | Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat | |
DK2161038T3 (da) | Sammensætninger og deres anvendelser rettet mod Huntington | |
DK2135603T3 (da) | Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet | |
DK2069312T3 (da) | Pyridazinonderivater | |
BRPI0716325A2 (pt) | Composição antimicrobianas | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
FR2899479B1 (fr) | Composition cicatrisante | |
DK3308788T3 (da) | Sammensætninger og fremgangsmåder til modulering af smn2-splejsning | |
DE602007012130D1 (de) | Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
DE502006006590D1 (de) | Biozide zusammensetzungen | |
DE602007012648D1 (de) | Härtbare Zusammensetzung | |
DE602006010127D1 (de) | Härtbare Zusammensetzung | |
DK3263112T3 (da) | Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer | |
DE602007004820D1 (de) | Härtbare Zusammensetzung | |
DK1920064T3 (da) | Sammensætninger og fremgangsmåder til forøgelse af amplifikationseffektiviteten | |
DK2097068T3 (da) | Formuleringer af peg-interferon-alpha-konjugater | |
DK2334596T3 (da) | Ferriphosphatbaseret sammensætning og anvendelse heraf | |
DK2262525T3 (da) | Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme | |
DK2068935T3 (da) | Polymerkonjugater af box-A af HMBG1 og boks-A-varianter af HMBG1 |